Nistor I, et al. - This study involved a comparison between single renin–angiotensin–aldosterone system (RAAS)-blocking agents vs placebo or alternative antihypertensive agents in the treatment of adult patients with diabetes who also had non-dialysis chronic kidney disease (CKD) stages 3–5. No clear survival benefit of RAAS-blocking agents was noted in this patient population. In addition, the selected outcome measure determined the impact on renal outcomes. However, no evidence demonstrated that the use of RAAS-blocking agents expedited the need for renal replacement therapy in patients with CKD stages 3–5.